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Management of acute postoperative hypertension for reducing cardiovascular
complications in cancer patients: when and how aggressively?
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Background/aim: We sought to determine what factors cardiovascular complications (CVCs) correlate with in cancer patients with
acute postoperative hypertension (APH) and to define when and how aggressively to treat this disorder in the present study.
Materials and methods: A retrospective observational study of cancer patients with postoperative hypertension at a single intensive
care unit between July 2007 and June 2013 was conducted. The outcome of interest was the incidence of a CVC.
Results: There were 1162 patients enrolled, of which 92 (7.9%) experienced one or more CVCs. Preexisting hypertension (OR 38.3,
95% CI 3.2–457.4, P = 0.004) and choice of vasodilator (OR 6.5, 95% CI 2.3–18.6, P = 0.000) were predictors of a CVC. Cardiovascular
complications were less likely to occur if pain was relieved efficiently during the postoperative period (OR 15.9, 95% CI 1.9–130.1, P =
0.01). Furthermore, there were increased CVCs among patients with postoperative hypertensive crises compared to those with stage 1
or stage 2 hypertension with the treatment threshold for systolic blood pressure (OR 5.7, 95% CI 2.0–16.5, P = 0.001) or diastolic blood
pressure (OR 6.0, 95% CI 1.8–20.3, P = 0.004).
Conclusion: To reduce CVCs, APH may be defined and managed as a hypertensive crisis in cancer patients.
Key words: Acute postoperative hypertension, cardiovascular complication, cancer, surgery

1. Introduction
The immediate postoperative period is a time of increased
risk of complications in surgical patients, with the
blood pressure frequently affected. Acute postoperative
hypertension (APH) refers to abnormally increased blood
pressure in the period, which usually occurs in patients
undergoing major surgery including cardiothoracic,
vascular, head and neck, and neurological surgery (1–6).
The reported frequency of APH varies with different
surgical procedures, and the incidence is relatively higher
in cardiovascular surgery (1–6). No standard definition of
APH exists, making the variability in reported incidence
difficult to reconcile (5–7).
The present reports describe that APH usually occurs
within 2 h after surgery, and the duration is usually 6 h
or less (4–7) and complications are higher if the elevated
blood pressure lasts longer than 3 h (5). Therefore, most
physicians agree that aggressive antihypertensive treatment
is necessary for APH to prevent the incidence of severe
complications. However, most commonly, 140/90 mmHg
* Correspondence: louning@sysucc.org.cn
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is the quoted threshold for the treatment of hypertension
in cardiac surgery (4,5,7,8). For most noncardiac types of
surgery, there is a lack of agreement about when and how
aggressively to treat APH (4, 5, 7). The treatment thresholds
used in clinical trials of postoperative hypertension have
included either a fixed blood pressure value (e.g., blood
pressure of >160/90 mmHg, or mean arterial pressure
of >110 mmHg) or a relative change from baseline (e.g.,
an increase in systolic or diastolic pressure of ≥20%) (5).
In our center, physicians apply the criteria for chronic
primary hypertension to diagnose APH (9), and treatment
of APH is frequently a bedside decision based on their
professional backgrounds. Thus, how to manage APH in
cancer patients has not been clearly established.
APH is due mainly to increased sympathetic tone and
vascular resistance (10,11). Contributing factors may also
include pain and increased intravascular volume (11).
However, acute or chronic hypertension may or may not
occur in the face of a shifted autoregulatory perfusion
curve and may result in the need for higher blood pressure
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to perfuse end organs (11,12). This situation makes it
very challenging to control blood pressure after surgery
(11). Therefore, precisely describing the epidemiology
of APH in this patient population who receive surgical
tumor resection, as well as identifying any modifiable risk
factors contributing to the development of cardiovascular
complications (CVCs), is important to determine when
and how aggressively to treat APH.
2. Materials and methods
2.1. Patients and ethics
Ethical approval for this study was provided by the Ethics
Committee of Sun Yat-Sen University Cancer Center,
Guangzhou, China. We performed anonymous analysis of
routinely collected clinical data. The ethics committee of
our institution waived the need for informed consent. A
retrospective, observational study of cancer patients with
APH at a single intensive care unit (ICU) between July 2007
and June 2013 was then conducted. A total of 9105 patients
for anesthesia care were admitted to the intensive care unit
(ICU). Eligible patients were identified by searching our
billing database for the term “hypertension” as the primary
procedure. Inclusion criteria were as follows: hypertension
occurred within 24 h after surgery with systolic blood
pressure (SBP) ≥140 mmHg and/or diastolic blood
pressure (DBP) ≥90 mmHg; patients received a shortacting vasodilator for APH; patients received no longacting vasodilator within 24 h after surgery. Exclusion
criteria were: patients with a previous history of coronary
heart disease, the same type of arrhythmia before and
after operation, or incomplete clinical data. A total of
1184 patients met the inclusion criteria and their charts
were systematically reviewed. A total of 1162 patients
were included and 22 patients were excluded, including
21 patients with preoperative arrhythmia or myocardial
ischemia and 1 due to incomplete medical records.
2.2. Clinical variables
Preoperative medical comorbidities and preoperative
smoking or drinking history were recorded from admission
history documents. Duration of anesthesia was obtained
from anesthetic records. ICU stay was recorded from
hospital charts. After operation, patients were sent to the
ICU under continuous monitoring of electrocardiograph,
blood pressure, and blood oxygen saturation for 48 h. For
the patients with postoperative hypertension, the following
parameters were recorded: types of CVCs, vasodilators
used, duration of anesthesia and types of surgery, pain
grade (visual analog score, VAS) of postoperative analgesia,
urine volume, and central venous pressure (CVP).
All patients received general anesthesia with tracheal
intubation and postoperative analgesic pump therapy
(with 25 mg of morphine for 48 h, 0.5 mg/h) after surgery.
Vital signs, including blood pressure, and CVCs were

recorded every 30 min. The postoperative course during
ICU stay included CVCs within 48 h after surgery. When
postoperative hypertension occurred, doctors determined
the need for treatment and selected the vasodilator to be
administered. Due to the lack of standard definition or
treatment threshold in noncardiac surgery, the doctors’
professional background was an important factor affecting
their decision to initiate treatment and the goals of blood
pressure control. Medications included the following:
sublingual nifedipine tablets (South China Pharmaceutical
Group Ltd., Guangdong, China), intravenous injection
of urapidil (Nycomed GmbH, Singen, Germany), and
nitroglycerin (Shanxi Kangbao Biological Products
Co., Ltd., Shanxi, China), infused intravenously by a
micropump.
The primary outcome of interest was the incidence of
CVCs, including arrhythmia, myocardial ischemia, and
heart failure, which were defined using standard diagnostic
criteria (13). Based on the Joint National Committee (JNC)
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure, according to the most recent report,
JNC7, patients were classified into three groups: stage 1
hypertension (SBP 140–159 mmHg and/or DBP 90–99
mmHg), stage 2 hypertension (SBP 160–179 mmHg and/
or DBP 100–109 mmHg), and hypertensive crisis (SBP
≥180 mmHg and/or DBP ≥110 mmHg) (10). For choice
of vasodilator, patients were split into three groups:
nitroglycerin-, urapidil-, and nifedipine-treated patients.
The patients were further divided into a group with highrisk surgery that included thoracic or cerebral surgery and
a group with low-risk surgery that included all other types
of surgery. The patients were also divided into two groups
based on goal of blood control (yes or no), intraoperative
blood loss (<300 or ≥300 mL), pain grade (VAS score of
<5 or ≥5), and CVP (<10 mmHg or ≥10 mmHg). There
is no treatment goal for postoperative hypertension after
noncardiac surgery. Based on our review of the literature,
the patients were stratified based on a 20% reduction of SBP
or DBP 3 h after antihypertensive treatment (11,14,15).
2.3. Statistical analysis
Data were collected by a single researcher. All authors
agreed on the definitions of CVCs prior to the
commencement of data collection. Data were presented
as mean (±SD) or number (proportion). Univariable
analyses were conducted using two-tailed t-testing, chisquare analysis, and Fisher’s exact test where appropriate.
Significant univariate predictors, identified at P < 0.05,
were then entered into multivariable logistic regression
analysis to identified independent predictors. All statistical
analyses were performed with SPSS 14 (SPSS Inc., Chicago,
IL, USA), and P < 0.05 was considered significant.
Manuscript preparation was done in accordance with the
Strengthening the Reporting of Observational Studies
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in Epidemiology (STROBE) Statement: Guidelines for
Reporting Observational Studies [16].
3. Results
In this study, patients were predominantly male (69.3%)
and the median age (SD) at the time of surgery was 61.1
(12.5) years. Median weight (SD) was 62.5 (15.7) kg and
43.3% or 19.7% of patients had a smoking or drinking
history, respectively. Comorbidity was documented in 623
cases (53.6%). The most prevalent medical comorbidity
was hypertension (39.0%), followed by diabetes mellitus
(8.7%). The rate of high-risk surgery, which included
thoracic or cerebral surgery, was 47.5%. The majority of
patients (62.9%) were operated on for less than 4 h, and the
blood loss during operation was less than 300 mL in 71.6%
of patients (Table 1).
In 9105 patients undergoing surgery, 1184 patients
suffered from postoperative hypertension, and the
incidence was 13.0% (defined as blood pressure ≥140/90
mmHg).The initial mean treatment threshold of SBP was
160.6 mmHg (147–206 mmHg) and DBP was 97.6 mmHg
(81–124 mmHg) in the 1162 patients not excluded from
our study (Table 2). After treatment with a short-acting
vasodilator for 3 h, SBP fell by 12.9% and DBP fell by 6.7%,
respectively.
Overall, our analysis revealed that 92 out of 1162
patients (7.9%) developed one or more postoperative CVCs.
The most frequently observed CVC was an arrhythmia
without hemodynamic change (n = 87). Eighty-seven
patients (94.6%) experienced a single CVC, and 5 patients
(5.4%) who experienced myocardial ischemia or heart
failure developed two or more complications. Twentynine episodes of sinus tachycardia, 27 episodes of atrial
premature contraction, 26 episodes of atrial fibrillation, 11
episodes of ventricular premature contraction, 7 episodes
of supraventricular tachycardia, 4 cases of myocardial
ischemia, and 1 case of heart failure were observed (Table
3). The overall incidence of severe CVCs falls to 5 out
of 92 (5.4%) when the patient who experienced isolated
arrhythmia is removed from the analysis.
Table 4 shows the results of the univariate analysis
performed to determine the significance for the variables
to predict the development of CVCs. A preoperative
diagnosis of hypertension was the only medical
comorbidity significantly associated with a CVC (P =
0.013). Development of CVCs was significantly associated
with the choice of vasodilator, and the incidence of
CVCs was 6.5% and 6.1% in the urapidil-treated and
nifedipine-treated patients, respectively, but 17.6% in the
nitroglycerin-treated patients (P = 0.000). Those with
pain relieved efficiently during the postoperative period
developed fewer CVCs compared to those without (P =
0.007). Furthermore, there were increased CVCs among
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Table 1. Demographic and clinical variables for patients with
postoperative hypertension (n = 1162)
Total patients, no. (%)

1162 (100)

Male, no. (%)

805 (69.3)

Age, mean (SD), years

61.1 (12.5)

Weight, mean (SD), kg

62.5 (15.7)

Smoking history, no. (%)

503 (43.3)

Drinking history, no. (%)

229 (19.7)

Diagnosis, no. (%)
Lung cancer

259 (22.3)

Esophageal cancer

212 (18.2)

Intracranial tumor

81 (7.0)

Colorectal cancer

196 (16.9)

Gastric cancer

141 (12.1)

Liver cancer

130 (11.2)

Urologic cancer

24 (2.1)

Gynecological cancer

20 (1.7)

Head and neck cancer

13 (1.1)

Other cancer

86 (7.4)

Medical comorbidity, no. (%)
Hypertension

453 (39.0)

Diabetes mellitus

101 (8.7)

COPD

54 (4.6)

CVA/TIA

8 (0.7)

Chronic renal failure

7 (0.6)

Duration of operation, no. (%)
Duration of anesthesia, <4 h

731 (62.9)

Blood loss, <300 mL

832 (71.6)

COPD, Chronic obstructive pulmonary disease; CVA,
cerebrovascular accident; TIA, transient ischemic attack; SD,
standard deviation.

patients with postoperative hypertensive crises compared
to those with stage 1 or stage 2 hypertension with the
treatment threshold for SBP (16.7% vs. 7.0% vs. 7.5%, P
= 0.012) or DBP (12.8% vs. 8.3% vs. 6.5%, P = 0.049). The
incidence of CVCs in the patients who achieved the goal
of blood pressure control and the patients who did not
were 7.1% and 8.2%, respectively (P = 0.732). Moreover,
there was no association between any of male sex, age,
body weight, smoking, drinking, diabetes mellitus, type of
surgery, duration of anesthesia, intraoperative blood loss,
or CVP and CVCs (P > 0.05) (Table 4). All of the severe
CVCs, including 4 cases of myocardial ischemia and
1 case of heart failure, developed in cases of preexisting
hypertension combined with hypertensive crisis patients.
No patients died in the ICU stay within 48 h.
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Table 2. Initial treatment threshold for systolic and diastolic
blood pressure in the study.
Mean (SD)

Minimum

Maximum

SBP

160.6 (12.2)

147

206

DBP

97.6 (10.4)

81

124

SBP, Systolic blood pressure; DBP, diastolic blood pressure; SD,
standard deviation.

Multivariate logistic regression analysis was
conducted using input parameters as follows: preexisting
hypertension, treatment threshold for systolic blood
pressure or diastolic blood pressure, choice of vasodilator,
and analgesia (Table 5). The full model containing all
predictors was statistically significant (P = 0.000). Five
of the variables were independent predictors of CVCs.
Preexisting hypertension (OR 38.3 [95% CI 3.2–457.4], P
= 0.004) and choice of vasodilator (OR 6.5 [95% CI 2.3–
18.6], P = 0.000) were predictors of a CVC. Cardiovascular
complications were less likely to occur if pain was
relieved efficiently during the postoperative period (OR
15.9 [95% CI 1.9–130.1], P = 0.01). Furthermore, there
were increased CVCs among patients with postoperative
hypertensive crises compared to those with stage 1 or stage
2 hypertension with the treatment threshold for SBP (OR
5.7 [95% CI 2.0–16.5], P = 0.001) or DBP (OR 6.0 [95% CI
1.8–20.3], P = 0.004).
4. Discussion
Acute postoperative hypertension is a common
complication after any major surgery. Different incidences
have been reported in the literature of 1.1%–60% (5,17–20).
In this study, the incidence of postoperative hypertension
was congruent with previous data regarding postoperative

hypertension in patients undergoing noncardiac surgery.
Acute postoperative hypertension has an early onset and is
typically of short duration (4–7). The risk factors for APH
include the surgical technique, duration of anesthesia,
patient characteristics, and pain management strategy (5).
However, elevation of SBP or DBP in primary hypertension
is associated with cardiovascular complications (21–23).
Clinical guidelines suggest that when blood pressure is
higher than 140/90 mmHg, antihypertensive treatment
should be administrated in order to reduce the mortality
rate and the occurrence of myocardial infarction, heart
failure, or other cardiovascular complications (10,24).
In contrast, for APH, the significance of transient
postoperative increases in blood pressure, the definition,
the treatment threshold and goal, and the potential adverse
effects of vasodilators are debated (5).
In this study, the incidence of CVCs in postoperative
hypertensive patients was 7.9%; there was only 1 case
of heart failure and 4 cases of myocardial ischemia. The
other cases were arrhythmias. The overall incidence of
severe cardiovascular complications markedly decreased
when the patient who experienced isolated arrhythmia is
removed from the analysis. Therefore, the present data are
unable to fully describe the relationship between severe
CVCs and correlated risk factors. The incidence of cardiac
arrhythmia was the major outcome in this study.
A high incidence of cardiac arrhythmia was found in
these patients diagnosed with primary hypertension before
operation. Furthermore, all of the severe complications,
including 1 case of heart failure and 4 cases of myocardial
ischemia, were also found in these patients. Patients with
untreated severe hypertension have a higher incidence
of stroke, myocardial ischemia, and renal failure because
of chronic changes in the autoregulation of end organ
perfusion (4–7). Postoperative hypertension is due mainly
to increased sympathetic tone and vascular resistance in

Table 3. Frequency of individual postoperative cardiovascular complications (n = 92).
Complications

Number of CVCs

Proportion of total CVCs (%)

Sinus tachycardia

29

27.6

Atrial premature contraction

27

25.7

Atrial fibrillation

26

24.8

Ventricular premature contraction

11

10.5

Supraventricular tachycardia

7

6.7

Myocardial ischemia

4

3.8

Heart failure

1

0.9

Total

105*

100

CVC, cardiovascular complication. *Several patients experienced more than one cardiovascular
complication.
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Table 4. Univariate analysis to determine the variables for cardiovascular complications in all 1162 patients with postoperative
hypertension.
Variables

Total (n = 1162)

Patients without
CVCs (n = 1070)

Patients with
CVCs (n = 92)*

P

Male, no. (%)

805 (69.3)

747(70.8)

58 (63.0)

0.177

Age, mean (SD), years

61.1 (12.5)

60.5 ( 12.1)

62.4 (10.7)

0.254

Weight, mean ( SD), kg

62.5 (15.7)

61.5 (17.4)

62.9 (13.9)

0.129

Smoker, no. (%)

503 (43.3)

463 (41.3)

40 (43.4)

0.969

Drinking habit, no. (%)

229 (19.7)

211 (19.7)

18 (20.0)

0.971

Hypertension

453 (39.0)

406 (37.9)

47 (51.1)

0.013

Diabetes mellitus

101 (8.7)

91 (8.5)

10 (10.9)

0.440

Surgery type, high-risk

552 (47.5)

501 (46.8)

51 (55.4)

0.112

Anesthesia, ≥4 h

431 (37.1)

396 (37.0)

35 (38.0)

0.844

Blood loss, ≥300 mL

330 (28.4)

311 (29.1)

26 (28.3)

0.870

Treatment threshold, SBP ≥180 mmHg

78 (6.7)

65 (6.1)

13 (14.1)

0.012

Treatment threshold, DBP ≥110 mmHg

133 (11.5)

116 (10.8)

17 (18.5)

0.049

Goal of BP control, yes

599 (51.5)

550 (51.4)

49 (53.3)

0.732

Choice of vasodilator, nitroglycerin

159 (13.7)

131 (12.2)

28 (30.4)

0.000

Analgesia, VAS <5

953 (82.0)

887 (82.9)

66 (58.7)

0.007

CVP, ≥10 mmHg

304 (26.2)

279 (26.1)

25 (27.2)

0.818

Comorbidity, no. (%)

Duration of operation, no. (%)

Postoperative management, no. (%)

BP, Blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; VAS, visual analog score; CVP, central venous pressure;
CVC, cardiovascular complications; SD, standard deviation. *Several patients sustained more than one cardiovascular complication.

patients with underlying primary hypertension (10,11).
Therefore, for cancer patients, primary hypertension
should be fully evaluated and managed before operation.
Candidates for tumor resection should continue their
antihypertensive medications through the morning of
surgery and then resume the medications as soon as
possible after the procedure (10,11). In addition, cardiac
arrhythmic events are often observed in cancer patients
undergoing thoracic surgery, and the possibility that they
were caused by surgical trauma cannot be excluded (25).
However, our study failed to detect a difference in the
incidence of CVCs in the patients with high-risk surgery,
including thoracic surgery, compared to those with lowrisk surgery, in contrast to contemporary reports (25).
Moreover, the effects of selection of duration of anesthesia
and operation, and intraoperative blood loss on the
development of postoperative CVCs, especially on cardiac
arrhythmia, were small in this study.
Regarding postoperative management, it is standard
practice in our institution to treat postoperative
hypertensive patients with antihypertensive medications
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when the blood pressure is over 140/90 mmHg. It is
possible that routine postoperative antihypertension does
not predispose these patients to CVCs; however, when and
how aggressively to treat hypertension in the immediate
postoperative period has not been clearly established.
Table 5. Multivariable analysis to determine the predictors
for cardiovascular complications in all 1162 patients with
postoperative hypertension.
Variables

OR (95% CI)

P

Hypertension

38.3 (3.2–457.4)

0.004

Choice of vasodilator

6.5 (2.3–18.6)

0.000

Treatment threshold, SBP

5.7 (2.0–16.5)

0.001

Treatment threshold, DBP

6.0 (1.8–20.3)

0.004

Analgesia, VAS <5

15.9 (1.9–130.1)

0.01

SBP, Systolic blood pressure; DBP, diastolic blood pressure; VAS,
visual analog score.
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In this study, we found that there were increased CVCs
among the patients with hypertensive crises, and all
of the severe CVCs occurred in these patients. Thus, a
postoperative hypertensive crisis may conceivably elevate
the risk of sustaining a CVC, and the high incidence of
CVCs observed is less surprising when severe hypertension
is considered. The incidence of CVCs in patients with
stage 1 or stage 2 postoperative hypertension was lower.
Furthermore, the incidence of CVCs between the patients
who achieved the goal of blood pressure control quoted in
this study and the patients who did not were not markedly
different. Therefore, we propose that APH may be defined
as a classification of a hypertensive crisis, and patients
with hypertensive urgency should have their blood
pressure reduced within 24 to 48 h, whereas patients with
hypertensive emergency should have their blood pressure
lowered immediately. In addition, we found that the
treatment of postoperative hypertension with intravenous
nitroglycerin administered by micropump was a factor
for CVCs. It may be due to the rapid and strong effect of
nitroglycerin to lower blood pressure leading to adverse
events, such as sinus tachycardia. This somewhat conflicts
with the report of Bussmann et al., which implied
that there was not significant difference in side effects
between nitroglycerin and nifedipine in the treatment of
hypertension (26). We thought that it may be because of
using nitroglycerin sublingually, not being administered by
micropump. These data suggest that this antihypertensive
strategy did not significantly reduce complications, but the
antihypertensive treatment induced somewhat an increase
of adverse events. On the other hand, postoperative pain
can cause agitation, anxiety, nervousness, and fear in
patients, resulting in an increase in catecholamines and
angiotensin, which would elevate myocardial automaticity
and excitability, leading to cardiac arrhythmias (25). For
the pain of incisions, regular analgesics are generally used.
In this study, a VAS score of <5 was found in the majority
of patients (82.0%), and fewer CVCs developed in these
patients. Therefore, pain being relieved efficiently is useful
for reducing CVCs in hypertensive patients after tumor
resection.

The impact of primary hypertension on survival
results mainly from the long-term contraction of small
arteries leading to gradual changes in internal organs
and pathological lesions in vital organs, such as the heart,
which ultimately results in death (27,28). However, APH is
mainly due to vasoconstriction of the resistance vessels in
the circulatory system under a stress condition, and these
events are often temporary and self-correcting (4–7,29–
31). Thus, except for a hypertensive crisis, postoperative
hypertension might not be sufficient to cause damage
to vital organs such as heart and result in CVCs. Due to
differences in etiology and pathological processes between
primary and postoperative hypertension, we suggest that
it is inappropriate to apply the classification system and
management guidelines for chronic hypertension to the
treatment of postoperative hypertension.
Our study demonstrated that postoperative hypertension
in cancer patients is common. Those who developed CVCs
were more likely to have preexisting hypertension and side
effects of vasodilators. Pain relieved efficiently decreased
the development of CVCs. There were increased CVCs
among the patients with hypertensive crises. Postoperative
stage 1 or stage 2 hypertension itself did not increase the
development of CVCs, and short-acting vasodilators did not
decrease the developed CVCs. Therefore, to reduce CVCs,
APH may be defined and managed as a hypertensive crisis
in cancer patients. Regarding postoperative stage 1 or stage
2 hypertension, preexisting hypertension and potentially
reversible causes, such as postoperative pain, should be
carefully managed, but routine short-acting vasodilators
may not be used.
Our study has several limitations. First, this work was a
retrospective study that investigated patients with APH after
surgery. Hence, the study may be subject to recruitment bias.
Second, it is essential to acknowledge that postoperative
hypertension is due mainly to increased sympathetic tone
(11), which results in CVCs, including arrhythmia. In the
present study, the incidence of cardiac arrhythmia was
the major complication. Although administration of beta
blockers is preferred to prevent CVCs, in our center, they
are rarely used regardless of preoperation or postoperation
timing during the study period.
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